{"organizations": [], "uuid": "3f2bb0a35134aee0b78b7ad090df2c49a6eec357", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "", "site_section": "http://www.cnbc.com/id/10000027/page/4", "section_title": "Press Releases - CNBC", "url": "http://www.cnbc.com/2018/05/03/pr-newswire-allergan-declares-second-quarter-2018-cash-dividend-of-0-point-72-per-ordinary-share.html", "country": "US", "domain_rank": 767, "title": "Allergan Declares Second Quarter 2018 Cash Dividend of $0.72 Per Ordinary Share", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.105, "site_type": "news", "published": "2018-05-04T00:30:00.000+03:00", "replies_count": 0, "uuid": "3f2bb0a35134aee0b78b7ad090df2c49a6eec357"}, "author": "cnbc.com", "url": "http://www.cnbc.com/2018/05/03/pr-newswire-allergan-declares-second-quarter-2018-cash-dividend-of-0-point-72-per-ordinary-share.html", "ord_in_thread": 0, "title": "Allergan Declares Second Quarter 2018 Cash Dividend of $0.72 Per Ordinary Share", "locations": [], "entities": {"persons": [{"name": "direc", "sentiment": "negative"}], "locations": [{"name": "dublin", "sentiment": "none"}, {"name": "ireland", "sentiment": "none"}, {"name": "dublin", "sentiment": "none"}], "organizations": [{"name": "allergan", "sentiment": "negative"}, {"name": "nyse", "sentiment": "negative"}, {"name": "allergan plc", "sentiment": "negative"}, {"name": "allergan plc allergan plc", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "DUBLIN, May 3, 2018 /PRNewswire/ -- Allergan plc (NYSE: AGN) today announced that its Board of Directors has declared a cash dividend of $0.72 per ordinary share for the second quarter of 2018. The dividend will be paid on June 15, 2018 to shareholders of record at the close of business on May 18, 2018.\nAbout Allergan plc\nAllergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a bold, global pharmaceutical leader. Allergan is focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world.\nAllergan markets a portfolio of leading brands and best-in-class products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women's health, urology and anti-infective therapeutic categories.\nAllergan is an industry leader in Open Science, a model of research and development, which defines our approach to identifying and developing game-changing ideas and innovation for better patient care. With this approach, Allergan has built one of the broadest development pipelines in the pharmaceutical industry.\nAllergan's success is powered by our global colleagues' commitment to being Bold for Life. Together, we build bridges, power ideas, act fast and drive results for our customers and patients around the world by always doing what is right.\nWith commercial operations in approximately 100 countries, Allergan is committed to working with physicians, healthcare providers and patients to deliver innovative and meaningful treatments that help people around the world live longer, healthier lives every day.\nFor more information, visit Allergan's website at www.Allergan.com .\nForward-Looking Statement\nStatements contained in this press release that refer to future events or other non-historical facts are that reflect Allergan's current perspective on existing trends and information as of the date of this release. Actual results may Allergan's current expectations depending upon a number of factors affecting Allergan's business. These factors include, among others, the difficulty of predicting the timing or outcome of FDA approvals or actions, if any; the impact of competitive products and pricing; market acceptance of and continued demand for Allergan's products; the impact of uncertainty around timing of generic entry related to key products, including RESTASIS Â® , on our financial results; uncertainty associated with financial projections, projected cost reductions, projected synergies, restructurings, increased costs, and adverse tax consequences; difficulties or delays in manufacturing; and other risks and uncertainties detailed in Allergan's periodic public filings with the Securities , including but not limited to Allergan's Annual Report on Form 10-K for the year ended December 31, 2017 and Allergan's Quarterly Report on Form 10-Q for the period ended March 31, 2018. Except as expressly required by law, Allergan disclaims any intent or obligation to update these .\nCONTACTS:\nAllergan:\nInvestors:\nDaphne Karydas\n(862) 261-8006\nKarina Calzadilla\n(862) 261-7328\nMedia:\nAmy Rose\n(862) 289-3072\nLisa Brown\n(862) 261-7320\nView original content with multimedia: http://www.prnewswire.com/news-releases/allergan-declares-second-quarter-2018-cash-dividend-of-0-72-per-ordinary-share-300642434.html\nSOURCE Allergan plc", "external_links": ["https://c212.net/c/link/?t=0&l=en&o=2123894-1&h=696871910&u=http%3A%2F%2Fwww.allergan.com%2F&a=www.Allergan.com", "http://www.prnewswire.com/news-releases/allergan-declares-second-quarter-2018-cash-dividend-of-0-72-per-ordinary-share-300642434.html"], "published": "2018-05-04T00:30:00.000+03:00", "crawled": "2018-05-04T02:27:27.007+03:00", "highlightTitle": ""}